tirzepatide patent expiry in india Novo Nordisk opens door to cheaper weight-loss drugs As the patent for semaglutide,

Additionally, there are patient assistance programs offered by the manufacturer, as well as discounts and coupons available through various channels that can help reduce the out-of-pocket expenses

That is the answer for every FDA-approved oral GLP-1 tablet currently on the market

O.CayumanF.et al (2020)

86% of adults taking Wegovy lost 5% or more weight, compared to 31% taking placebo 69% of adults taking Wegovy lost 10% or more weight, compared to 12% taking placebo 51% of adults taking Wegovy lost 15% or more weight, compared to 5% taking placebo* About 1 in 3 adults lost 46 lb or more (20% weight loss) while only 1.7% of adults on placebo experienced the same weight loss

GLP-1 medications without insurance February